During the last session, Viracta Therapeutics Inc (NASDAQ:VIRX)’s traded shares were 0.62 million, with the beta value of the company hitting 0.74. The 52-week high for the VIRX share is $1.52, that puts it down -245.45 from that peak though still a striking 2.27% gain since the share price plummeted to a 52-week low of $0.43. The company’s market capitalization is $17.33M, and the average intraday trading volume over the past 10 days was 0.13 million shares, and the average trade volume was 100.17K shares over the past three months.

Viracta Therapeutics Inc (VIRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. VIRX has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.37.

Viracta Therapeutics Inc (NASDAQ:VIRX) trade information

Viracta Therapeutics Inc (VIRX) registered a 0.59% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.59% in intraday trading to $0.44, hitting a weekly high. The stock’s 5-day price performance is -0.61%, and it has moved by -11.70% in 30 days. Based on these gigs, the overall price performance for the year is -68.92%. The short interest in Viracta Therapeutics Inc (NASDAQ:VIRX) is 0.97 million shares and it means that shorts have 8.92 day(s) to cover.

The consensus price target of analysts on Wall Street is $8, which implies an increase of 94.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8 and $8 respectively. As a result, VIRX is trading at a discount of -1718.18% off the target high and -1718.18% off the low.

Viracta Therapeutics Inc (VIRX) estimates and forecasts

Statistics show that Viracta Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Viracta Therapeutics Inc (VIRX) shares have gone down -21.21% during the last six months, with a year-to-date growth rate less than the industry average at 6.06% against 16.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -15.60% this quarter and then jump 21.20% in the quarter after that.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 44.96%. While earnings are projected to return 10.35% in 2024.

VIRX Dividends

Viracta Therapeutics Inc is due to release its next quarterly earnings 2024-Aug-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Viracta Therapeutics Inc (NASDAQ:VIRX)’s Major holders

Viracta Therapeutics Inc insiders own 2.76% of total outstanding shares while institutional holders control 49.92%, with the float percentage being 51.34%. BVF INC/IL is the largest shareholder of the company, while 47.0 institutions own stock in it. As of 2024-03-31, the company held over 3.61 million shares (or 9.3585% of all shares), a total value of $3.69 million in shares.

The next largest institutional holding, with 1.57 million shares, is of CITADEL ADVISORS LLC’s that is approximately 4.0524% of outstanding shares. At the market price on 2024-03-31, these shares were valued at $1.6 million.

Also, the Mutual Funds coming in first place with the largest holdings of Viracta Therapeutics Inc (VIRX) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Mar 31, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 813.92 shares. This amounts to just over 2.07 percent of the company’s overall shares, with a $0.36 million market value. The same data shows that the other fund manager holds slightly less at 282.49, or about 0.72% of the stock, which is worth about $0.12 million.